Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
RecruitingNCT06927024Phase: NAStarted 2025-10-15
Summary
30 patients will participate in a prospective randomized clinical trial to test the safety, tolerability and efficacy of transcutaneous auricular vagus nerve stimulation (taVNS) for autonomic nervous
Eligibility
Sex
ALL
Min Age
18 Years
Max Age
None
Locations
NYU Langone HealthNew York, New York, United States
View full study details on ClinicalTrials.gov
clinicaltrials.gov/study/NCT06927024